Teva Pharmaceutical Industries

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20648
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7186
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 14 Jan 2017 08:02

Go with the flow.


Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20648
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7186
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 20 Jan 2017 08:43

Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Teva Pharmaceutical Industries Ltd. TEVA announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Teva's share price has declined 45% in the past one year, compared with the Zacks classified Medical-Generics Drugs industry's fall of 33%.
Vantrela, which is an extended-release formulation of hydrocodone bitartrate, has been developed utilizing the company's proprietary abuse deterrence technology. As expected, Vantrela's label carries a description regarding the product's abuse-deterrent properties that are likely to reduce, but not fully prevent abuse of the drug, when the tablets are manipulated. The label also contains a Boxed Warning that includes addiction, abuse and misuse, which can lead to overdose and even death, as well as serious or fatal respiratory depression.

Last year in August , another pharma giant Pfizer Inc. PFE received FDA approval for Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride), for oral use, CII, for the management of severe pain on regular basis, around-the-clock, long-term opioid treatment and for which alternative treatment options are insufficient.
" Zacks Equity Research"
Go with the flow.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20648
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7186
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 23 Jan 2017 20:02

Teva: Stock down but yield is up

Teva's dividend yield of 4.03% slightly lags behind AbbVie's. However, unlike both AbbVie and Gilead Sciences, the Israel-based drugmaker doesn't have much room for dividend hikes. Teva is using nearly 79% of earnings to cover its dividend right now. After a decade of increases, the company has kept its dividend payout steady over the last two years.

Investors probably don't need to worry about Teva's juicy yield being in jeopardy, though. The company should be able to grow earnings, albeit slowly perhaps, over the next few years. Teva's acquisition last year of Actavis Generics from Allergan will definitely help with increasing revenue and earnings.

But is Teva's stock slide over? Shares have dropped over 45% in the last 12 months with no signs yet of bottoming out. My view is that Teva likely won't fall too much below current levels, although I wouldn't go as far as predicting an imminent rebound.

The good news for investors is that Teva's stock is now cheaper than it's been in a while. Teva trades below seven times forward earnings.
January 22, 2017, 06:42:00 AM EDT By Keith Speights, Motley Fool
Go with the flow.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20648
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7186
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 27 Jan 2017 16:31

Here’s Why Teva Pharmaceuticals Industries Ltd (ADR) (TEVA) Is Bullish on 2017
Teva Pharmaceuticals Industries Ltd (ADR) (NYSE: TEVA ) has had a tough 2016, with TEVA stock off 44%-plus for the year.
Here's Why Teva Pharmaceuticals Industries Ltd (ADR) (TEVA) Is Bullish on 2017 Source: Open Grid Scheduler (Modified)

Some of it Teva brought on itself - a mega-merger for generics firm Actavis in 2015 meant it had to sell off some of its drugs and pipeline products to get regulatory clearance in the U.S. and Europe.

It also meant swallowing a very large company and building it into the existing corporate structure. TEVA stock spent most of 2016 sorting this out.

The acquisition also meant that Teva was focusing on developing its generics business over its specialty drugs. Its multiple sclerosis drugs made up 19% of revenue in 2016, but accounted for 41% of profits. In 2017, the company expects that this division will account for 16% of revenue and 36% of profits.

The difference will be made up in Teva's generics business. And Teva is the world's largest generics manufacturer. In 2016, generics accounted for 55% of revenues and 41% of corporate profits. The company estimates that in 2017 it will generate 58% of revenues from generics and those sales will account for 49% of profits.

10 High-Yield Dividend Stocks That Are SOMEHOW Still Bargains

This year is the year that Actavis is fully digested and Teva can deploy its new assets effectively. But the cost was a near-50% plunge in TEVA stock over the past 12 months while Teva sorted this and other challenges out.

The two challenges that top the list are the SEC corruption charges that Teva settled for half a billion dollars in Q4 2016. The other is the fate of its blockbuster central nervous system drug, Copaxone.

This is currently a nearly $4 billion a year drug for the company, but its patent is about to expire and there are at least two generics looking to get in on the action.

These two issues, along with the challenges in absorbing Actavis' business have been the leading causes for the cratering of TEVA stock. And President Trump's indication via tweet that he thinks drug prices are too high has put a dent in the broader biotech party that was going on until recently.

But the good news is, this all behind Teva. The case with SEC is settled and the analysts have already assumed the worst regarding Copaxone. If the generics lose their battle to get in on the action, that will be a very big win, and it wouldn't be especially surprising.

Also, because Teva is the leading generics producer in the US, it's a sure bet that as Obamacare gets rebuilt, generics will be a driving force to keep medical costs down. That will be a boon for TEVA stock, since it's the top generics maker in both the U.S. and Europe, with a growing base in emerging markets as well.

FireEye Inc (FEYE) Stock Will Never Make It Back to $20. Here's Why.

The simple fact is, there's far less downside than upside at this point. And TEVA stock comes with a very healthy 4.2% dividend at this point. That pays for your patience as the turnaround begins.

Richard Band's Profitable Investing advisory service helps retirement savers outperform the market without losing a minute of sleep along the way. His straightforward style and low-risk value approach has won seven Best Financial Advisory awards from the Newsletter and Electronic Publishers Foundation.
Go with the flow.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20648
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7186
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 27 Jan 2017 19:54

Is Teva Seeing a Dead Cat Bounce? Probably (TEVA)
By Michael Kramer | January 27, 2017 — 11:51 AM EST

It has not been a great start to 2017 for Teva (TEVA). However, theflyonthewall.com is reporting that Teva agreed to pay $225 million to settle an antitrust case in California. The suit alleged that Teva's Barr Pharmaceuticals deliberately did not produce a generic version of Cipro, an antibiotic. The story says that Bayer AG (BAYRY) paid Barr $398 million not to produce the generic version of the medicine. Teva's shares are up nearly 2.3% on the day to $34.71.

Drug pricing clearly is still in the news, and unfortunately, continues to be a heavyweight on the sector as a whole. Teva has had its problems outside of the drug pricing issue and provided weak 2017 guidance earlier this year. (See also, Teva Plummets on Weak Guidance)

Teva shares are trading near their lows, although the stock as had a mini-rally this past week, rising from around $32.50 to $34.70 since January 23rd. We could just be witnessing a bit of a dead cat bounce at this point. In my opinion, there has been nothing concrete and significant enough to see a change in the company's share price trend at this point.

In fact, if one looks at the chart of Teva, one can see there are several unyielding areas of resistance that could be approaching. The first at the $34.75-ish area and the next around $37. It is going to take a lot to get shares of Teva above those critical prices.
For Teva shareholders, the next event on the docket, that could help begin to turn the tide, will be its earnings release, which has yet to be scheduled. At that point, the market should get a fresh look at how the company is doing and perhaps Teva will have a plan for growth going forward.
Go with the flow.

kopke1
Forum gebruiker
Forum gebruiker
Berichten: 129
Lid geworden op: 15 Nov 2013 21:36
waarderingen: 73
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor kopke1 » 31 Jan 2017 09:44

Gisteren redelijk stand gehouden. zelfs even de 35 dollar aangeraakt maar nabeurs een oplawaai van bijna 10%. Buiten de tegenstrijdige analyses van analysten vind ik evenwel nergens nieuws dat deze mogelijk koersval zou verduidelijken.
charel01 liked last!

Gebruikersavatar
Zechs
Premiummember
Premiummember
Berichten: 800
Lid geworden op: 02 Jul 2013 20:01
waarderingen: 251
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor Zechs » 31 Jan 2017 09:53

kopke1 schreef:Gisteren redelijk stand gehouden. zelfs even de 35 dollar aangeraakt maar nabeurs een oplawaai van bijna 10%. Buiten de tegenstrijdige analyses van analysten vind ik evenwel nergens nieuws dat deze mogelijk koersval zou verduidelijken.



Ze verloren een rechtszaak rond patenten voor Copaxone (hun stermiddel) tegen Mylan. Ze gaan wel in beroep. Dit kan wel duur worden aangezien het gros van hun inkomsten uit Copaxone komen.
cicero007 liked last!
Eigenbelang primeert altijd

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20648
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7186
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 31 Jan 2017 11:33

Teva:
Een Amerikaanse rechter besliste dat de grootste producent van generische medicijnen ter wereld vier patenten verliest op zijn bestverkopende medicijn Copaxone voor multiple sclerose.
Blog KBC Bolero
Bij opening gaan mijn aandelen buiten. :roll:
Go with the flow.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 20648
Lid geworden op: 02 Jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 7186
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor charel01 » 31 Jan 2017 15:42

Om een of andere reden kreeg ik het aandeel langs geen kanten verkocht met een limietorder. Aandelen zijn verkocht met een marktorder 32,31.
Go with the flow.

Gebruikersavatar
johan1213
Forum gebruiker
Forum gebruiker
Berichten: 203
Lid geworden op: 31 Aug 2015 15:40
waarderingen: 64
Contact:

Re: Teva Pharmaceutical Industries

Berichtdoor johan1213 » 13 Feb 2017 13:23

Teva Pharmaceutical Industries
reported better-than- expected fourth-quarter profit



TEL AVIV, Feb 13 (Reuters) - Teva Pharmaceutical Industries
reported better-than- expected fourth-quarter profit
as sales were boosted by its $40.5 billion acquisition of
Allergan's Actavis generic drug business on Aug. 2.
Israel-based Teva said on Monday it earned $1.38 per share
excluding one-time items in the quarter, up from $1.28.
Revenue grew 33 percent to $6.5 billion, primarily due to
the inclusion of $630 million from the Actavis acquisition.
Teva TEVA.N was forecast to earn $1.35 excluding one-off
items on revenue of $6.24 billion, according to Thomson Reuters
I/B/E/S.
Teva was left without a permanent chief executive last week
after Erez Vigodman stepped down, leaving new management to
restore confidence in the world's biggest generic drugmaker
after a series of missteps.
Global sales of its best-selling multiple sclerosis drug
Copaxone rose 6 percent in the quarter to $1.0 billion.
Teva reaffirmed its 2017 forecast of earnings per share of
$4.90-$5.30 on revenue of $23.8 billion-$24.5 billion.
It will pay a quarterly dividend of 34 cents per ordinary
share and $17.50 per mandatory convertible preferred share